About the Authors
- Satoshi Kawano
-
Contributed equally to this work with: Satoshi Kawano, Alexandra R. Grassian
Affiliation Eisai Co., Ltd., Tsukuba, Ibaraki, Japan
- Alexandra R. Grassian
-
Contributed equally to this work with: Satoshi Kawano, Alexandra R. Grassian
* E-mail: agrassian@epizyme.com (ARG); sribich@epizyme.com (SR)
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Masumi Tsuda
-
Affiliation Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
- Sarah K. Knutson
-
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Natalie M. Warholic
-
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Galina Kuznetsov
-
Affiliation Eisai Inc., Andover, Massachusetts, United States of America
- Shanqin Xu
-
Affiliation Eisai Inc., Andover, Massachusetts, United States of America
- Yonghong Xiao
-
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Roy M. Pollock
-
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Jesse S. Smith
-
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Kevin K. Kuntz
-
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Scott Ribich
-
* E-mail: agrassian@epizyme.com (ARG); sribich@epizyme.com (SR)
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Yukinori Minoshima
-
Affiliation Eisai Co., Ltd., Tsukuba, Ibaraki, Japan
- Junji Matsui
-
Affiliation Eisai Co., Ltd., Tsukuba, Ibaraki, Japan
- Robert A. Copeland
-
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
- Shinya Tanaka
-
Affiliation Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
- Heike Keilhack
-
Affiliation Epizyme Inc., Cambridge, Massachusetts, United States of America
Competing Interests
ARG, SKK, NMW, YX, RP, JSS, KKK, SR, HK, and RAC are employees of, and/or hold equity in, Epizyme, Inc. SK, GK, SX, YM, and JM are employees of, and/or hold equity in, Eisai Co., Ltd or Eisai, Inc. Tazemetostat is in clinical development and the compound as well as its use in the treatment of cancer, including synovial sarcoma, is subject to several U.S. and international patents and patent applications, including, but not limited to, international PCT Application PCT/US2012/033648 filed April 13, 2012, and international PCT/US2014/061205, filed October 17, 2014. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: SK ARG MT SKK NMW GK SX YX RMP JSS KKK SR YM JM RAC ST HK. Performed the experiments: SK ARG MT SKK NMW GK SX. Analyzed the data: SK ARG MT SKK NMW GK SX YX RMP JSS KKK SR YM JM RAC ST HK. Wrote the paper: SK ARG SR RAC HK.